Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Kentucky Health Wire.
Press releases published on October 3, 2025
Angelini Ventures Leads €12 Million Follow-On Investment in Serenis, a Fast-Growing Digital Mental and Physical Health Company
Through its investment, Angelini Ventures aims to promote the expansion and acceleration of Serenis’ digital health and wellbeing services and amplify its leadership in delivering transformative solutions to corporate clients Investment represents a …
Appointment of Marc Le Bozec as Interim CEO
Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment …
Nomination de Marc Le Bozec comme Directeur Général par interim
Nomination de Marc Le Bozec comme Directeur Général par interim NANTES, France, 3 octobre 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce la cessation des fonctions de M. Nicolas Poirier en tant que Directeur Général, …
Santhera gibt die Zulassung von AGAMREE® (Vamorolon) in Kanada zur Behandlung von Duchenne-Muskeldystrophie bekannt
Health Canada hat AGAMREE für die Behandlung von Duchenne-Muskeldystrophie bei Patienten ab 4 Jahren zugelassen Mit dieser Zulassung ist AGAMREE das erste und einzige zugelassene Medikament zur Behandlung von DMD in Kanada Pratteln, Schweiz, 3. Oktober …
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 – Santhera …
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) J-Code …